Login
$JSPR
$12.41 +$0.64 (5.44%) After hours

$JSPR 8-K SEC Filings

Filed On Filing
16 Nov 2026 8-K: Results of Operations and Financial Condition

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

13 Nov 2026 8-K: Other Events
09 Nov 2026 8-K: Other Events

REDWOOD CITY, Calif., November 9, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat...

04 Nov 2026 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

REDWOOD CITY, Calif., November 4, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat...

15 Oct 2026 8-K: Other Events

Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy

07 Oct 2026 8-K: Other Events

REDWOOD CITY, Calif., October 7, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat ...

05 Oct 2026 8-K: Submission of Matters to a Vote of Security Holders

On September 30, 2026, Jasper Therapeutics, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, a total of 21,747,865 shares of the Company’s voting common stock, $0.0001 par value...

28 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

On September 23, 2026, Herb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Jasper Therapeutics, Inc. (the...

26 Aug 2026 8-K: Entry into a Material Definitive Agreement

On August 21, 2026, Jasper Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the stockholders’ equity reported in the Company’s Quarterly Repo...

14 Aug 2026 8-K: Results of Operations and Financial Condition

Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders

03 Aug 2026 8-K: Submission of Matters to a Vote of Security Holders

On July 31, 2026, Jasper Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, a total of 21,121,396 shares of the Company’s voting common stock, or approximately 7...

31 Jul 2026 8-K: Other Events

As previously disclosed by Jasper Therapeutics, Inc., a Delaware corporation (the “Company”), on a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission (the “SEC”) on July 16, 2026 (the “Prior Form ...

17 Jul 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +4 more

THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of July 16, 2026, by and among Jasper Therapeutics, Inc., a Delaware corporation (“Parent”), Kira Holdco Inc., a Delaware corporation and wholly owned Subsidiary of Parent (“M...

16 Jul 2026 8-K: Regulation FD Disclosure

Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders

09 Jun 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On June 3, 2026, Jasper Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s...

01 Jun 2026 8-K: Regulation FD Disclosure

REDWOOD CITY, Calif., June 1, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to ad...

21 May 2026 8-K: Departure/Election of Directors or Officers; Compensation

On May 15, 2026 (the “Notice Date”), Christian Nolet informed the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) that he is resigning from the Board and the committees of the Board on which he serves, effec...

14 May 2026 8-K: Results of Operations and Financial Condition

REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to ad...

30 Mar 2026 8-K: Results of Operations and Financial Condition

REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to ...

08 Jan 2026 8-K: Other Events

Jasper Therapeutics BEACON & OLE Data Update January 8, 2026 Exhibit 99.2

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support